Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Negative 89.7%

Neg 89.7% Neu 0% Pos 0%

Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $8 price target.